Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinryze for acute antibody-mediated rejection in donor-sensitized kidney transplant recipients
2012-000441-12Phase 2Completed
- Sponsor
- ViroPharma Incorporated
- Start
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Antibody-mediated kidney allograft rejection (AMR) and graft rejection comparing Cinryze with Placebo (2 arms). Primary endpoints: Histopathology and Safety and tolerability of Cinryze. Started Jun 2012; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
Antibody-mediated kidney allograft rejection (AMR)graft rejection
Beyond the preview
Go deeper on 2012-000441-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000441-12.